Kathryn Hayashi

Chief Executive Officer at

TRIUMF Innovations, Inc.

Health Technology

Consumer Services

Commercial Services

Profile

Kathryn Hayashi currently works at TRIUMF Innovations, Inc., as CEO from 2017, ARTMS, Inc., as Director from 2018, Nimbus Synergies, Inc., as Board of Director from 2017, and Centre For Commercialization of Cancer Immunotherapy, as Director.
Ms. Hayashi also formerly worked at Sitka Biopharma, Inc., as Director from 2016 to 2017, Zucara Therapeutics, Inc., as Director from 2015 to 2017, and The Centre for Drug Research & Development, as CFO from 2006 to 2017.
Ms. Hayashi received her undergraduate degree in 2000 from the University of British Columbia.

Kathryn Hayashi active positions

Companies	Position	Start
ARTMS, Inc. ARTMS, Inc. BiotechnologyHealth Technology Operates as a biotechnology company	Director/Board Member	28/03/2018
Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy BiotechnologyHealth Technology Manufactures cell and gene products	Director/Board Member	-
Nimbus Synergies, Inc. Nimbus Synergies, Inc. Investment ManagersFinance Nimbus Synergies invests in companies located in North America primarily in Canada and opportunistically in the United States with revenues of USD 0.5 - 2 million. The firm focuses on the health technology sector. It participates in pre-seed, seed and early stage capital requirements with an investment size of USD 0.25 - 5 million. The firm makes co-investments and also acts as a lead investor. It takes a seat on the board of directors. The firm makes follow-on investments and it does not invest in therapeutics and class III devices.	Director/Board Member	01/09/2017
TRIUMF Innovations, Inc. TRIUMF Innovations, Inc. Information Technology ServicesTechnology Services Provides information technology services	Chief Executive Officer	01/02/2017

All active positions of Kathryn Hayashi

Former positions of Kathryn Hayashi

Companies	Position	End
Sitka Biopharma, Inc. Sitka Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops novel polymer platform technology that improves drug absorption for cancer treatments	Director/Board Member	01/01/2017
Zucara Therapeutics, Inc. Zucara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drug therapy for hypoglycemia in type 1 diabetes people	Director/Board Member	01/01/2017
The Centre for Drug Research & Development The Centre for Drug Research & Development Miscellaneous Commercial ServicesCommercial Services Discovers, research and develops therapeutic products	Director of Finance/CFO	01/01/2017

See the detail of Kathryn Hayashi's experience

Training of Kathryn Hayashi

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Kathryn Hayashi's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	8
University of British Columbia University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
The Centre for Drug Research & Development The Centre for Drug Research & Development Miscellaneous Commercial ServicesCommercial Services Discovers, research and develops therapeutic products	Commercial Services
Sitka Biopharma, Inc. Sitka Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops novel polymer platform technology that improves drug absorption for cancer treatments	Health Technology
ARTMS, Inc. ARTMS, Inc. BiotechnologyHealth Technology Operates as a biotechnology company	Health Technology
Nimbus Synergies, Inc. Nimbus Synergies, Inc. Investment ManagersFinance Nimbus Synergies invests in companies located in North America primarily in Canada and opportunistically in the United States with revenues of USD 0.5 - 2 million. The firm focuses on the health technology sector. It participates in pre-seed, seed and early stage capital requirements with an investment size of USD 0.25 - 5 million. The firm makes co-investments and also acts as a lead investor. It takes a seat on the board of directors. The firm makes follow-on investments and it does not invest in therapeutics and class III devices.	Finance
Zucara Therapeutics, Inc. Zucara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drug therapy for hypoglycemia in type 1 diabetes people	Health Technology
TRIUMF Innovations, Inc. TRIUMF Innovations, Inc. Information Technology ServicesTechnology Services Provides information technology services	Technology Services
Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy BiotechnologyHealth Technology Manufactures cell and gene products	Health Technology